Evidence map›Paper›PMID 28664301›Full record

ArticleInternational journal of clinical oncology2017

Association of decreased mean platelet volume with renal cell carcinoma.

Zhi-Yuan Yun, Xin Zhang, Zhi-Ping Liu, Tiemin Liu, Rui-Tao Wang, Hui Chen

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Observational
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Zhi-Yuan YunDepartment of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, No. 150 Haping ST, Nangang District, Harbin, Heilongjiang, 150081, China.
Xin ZhangDepartment of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, No. 150 Haping ST, Nangang District, Harbin, Heilongjiang, 150081, China.
Zhi-Ping LiuDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Tiemin LiuDepartment of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, No. 150 Haping ST, Nangang District, Harbin, Heilongjiang, 150081, China.
Rui-Tao WangDepartment of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, No. 150 Haping ST, Nangang District, Harbin, Heilongjiang, 150081, China. ruitaowang@126.com.
Hui ChenDepartment of Urinary Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, No. 150 Haping ST, Nangang District, Harbin, Heilongjiang, 150081, China. dr_chenhui@yeah.net.
Harbin Medical University · CNThe University of Texas Southwestern Medical Center · USThird Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal cell carcinoma (RCC) is the third most common genitourinary cancer. Activated platelets play a pivotal role in cancer development and progression. Altered mean platelet volume (MPV) has been reported in several malignancies. The aim of the present study was to investigate the association of MPV with RCC. STUDY

designThe study consisted of 145 patients with RCC, 110 patients with benign renal tumor and 132 healthy control subjects between January 2015 and December 2015. All participants' clinical and laboratory characteristics at initial diagnosis were collected. The odds ratios (ORs) for RCC were calculated using multivariate logistic regression analysis after adjusting for confounding variables across MPV quartiles.

resultsThe patients with RCC had decreased pre-operative MPV compared to the patients with benign renal tumor and healthy control subjects. Furthermore, pre-operative MPV was reduced in benign renal tumor compared with healthy control subjects. Surgical tumor resection resulted in a significant increase in MPV levels (8.7 fL vs. 9.0 fL; p = 0.011). After adjusting for other risk factors, the ORs (95% CIs) for RCC in each MPV quartile were 25.725 (7.556-87.585), 7.447 (2.701-20.537), 0.703 (0.245-2.019), and 1.000, respectively.

conclusionsRCC patients have remarkably reduced MPV compared to patients with benign renal tumor and healthy control subjects. Moreover, decreased MPV was independently associated with RCC. Our results suggest that detection of MPV may be useful to assess the risk of RCC.

Indexed as

Mean Platelet VolumeAdultAgedAged, 80 and overCarcinoma, Renal CellCase-Control StudiesFemaleHumansKidney NeoplasmsMaleMiddle AgedOdds RatioRisk FactorsDiagnosisMean platelet volumeRenal cell carcinoma

Identifiers

PMID28664301
OpenAlexW2733488771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.